Transrectal ultrasound in detecting prostate cancer compared with serum total prostate-specific antigen levels

• Published in: Journal of medical imaging and radiation oncology Vol. 52; no. 1; pp. 24 - 28
• Main Authors: Tamsel, S, Killi, R, Hekimgil, M, Altay, B, Soydan, S, Demirpolat, G
• Format: Journal Article
• Language: English
• Published: Melbourne, Australia Blackwell Publishing Asia 01.02.2008
• Subjects: Aged; Aged, 80 and over; Biopsy; Diagnosis, Differential; Humans; Male; Middle Aged; Predictive Value of Tests; Prostate; prostate cancer; prostate-specific antigen; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - pathology; Rectum - diagnostic imaging; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; transrectal ultrasonography; Ultrasonography, Interventional - methods
• ISSN: 1754-9477; 1754-9485
• DOI: 10.1111/j.1440-1673.2007.01906.x

Summary We carried out a retrospective study to review the efficiency of grey‐scale transrectal ultrasonography (TRUS) in detecting prostate cancer compared with the data in recent published work, including alternative imaging methods of the prostate gland. Our study group consisted of 830 patients who underwent TRUS‐guided biopsy of the prostate between May 2000 and June 2004. The relation between abnormal TRUS findings and serum total prostate‐specific antigen (tPSA) levels was evaluated in patients with prostate cancer who were divided into three different groups according to serum tPSA levels. Group I included patients with tPSA levels of 4–9.9 ng/mL, group II included tPSA levels of 10–19.9 ng/mL and group III included patients with tPSA levels of 20 ng/mL or more. In general, TRUS detected 185 (64%) of 291 cancers with a specificity of 89%, a PPV of 76% and an accuracy of 80%. TRUS findings enabled the correct identification of 22 (56%) of the 39 cancers in group I, 28 (30%) of the 93 cancers in group II and 135 (85%) of the 159 cancers in group III. In conclusion, TRUS alone has a limited potential to identify prostate cancer, especially in patients with tPSA levels lower than 20 ng/mL. Therefore, increased numbers of systematically placed biopsy cores must be taken or alternative imaging methods are required to direct TRUS‐guided biopsy for improving prostate cancer detection.